Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, reflecting the absence of late-stage clinical trials and official CDC and WHO confirmation of no licensed vaccines or treatments for key strains like Andes virus causing hantavirus pulmonary syndrome. Recent multi-country cluster (11 cases, 3 deaths as of May 13 per WHO) on cruise ship MV Hondius has spotlighted preclinical efforts, including Moderna's mRNA candidate showing mouse protection in 2025 and University of Bath's stable antigen nearing human tests, alongside phase 1 DNA vaccines for Old World strains (Hantaan, Puumala) that elicited neutralizing antibodies but require phase 2 advancement. Experts estimate 3–10 years to full approval absent Operation Warp Speed-scale acceleration, with disease rarity hindering rapid progress; monitor upcoming phase initiations and funding shifts.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$83,411 Объем
$83,411 Объем
31 дек. 2026 г.
$83,411 Объем
$83,411 Объем
31 дек. 2026 г.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, reflecting the absence of late-stage clinical trials and official CDC and WHO confirmation of no licensed vaccines or treatments for key strains like Andes virus causing hantavirus pulmonary syndrome. Recent multi-country cluster (11 cases, 3 deaths as of May 13 per WHO) on cruise ship MV Hondius has spotlighted preclinical efforts, including Moderna's mRNA candidate showing mouse protection in 2025 and University of Bath's stable antigen nearing human tests, alongside phase 1 DNA vaccines for Old World strains (Hantaan, Puumala) that elicited neutralizing antibodies but require phase 2 advancement. Experts estimate 3–10 years to full approval absent Operation Warp Speed-scale acceleration, with disease rarity hindering rapid progress; monitor upcoming phase initiations and funding shifts.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Открытие рынка: May 4, 2026, 10:39 AM ET
Объем
$83,411Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, reflecting the absence of late-stage clinical trials and official CDC and WHO confirmation of no licensed vaccines or treatments for key strains like Andes virus causing hantavirus pulmonary syndrome. Recent multi-country cluster (11 cases, 3 deaths as of May 13 per WHO) on cruise ship MV Hondius has spotlighted preclinical efforts, including Moderna's mRNA candidate showing mouse protection in 2025 and University of Bath's stable antigen nearing human tests, alongside phase 1 DNA vaccines for Old World strains (Hantaan, Puumala) that elicited neutralizing antibodies but require phase 2 advancement. Experts estimate 3–10 years to full approval absent Operation Warp Speed-scale acceleration, with disease rarity hindering rapid progress; monitor upcoming phase initiations and funding shifts.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Объем
$83,411Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, reflecting the absence of late-stage clinical trials and official CDC and WHO confirmation of no licensed vaccines or treatments for key strains like Andes virus causing hantavirus pulmonary syndrome. Recent multi-country cluster (11 cases, 3 deaths as of May 13 per WHO) on cruise ship MV Hondius has spotlighted preclinical efforts, including Moderna's mRNA candidate showing mouse protection in 2025 and University of Bath's stable antigen nearing human tests, alongside phase 1 DNA vaccines for Old World strains (Hantaan, Puumala) that elicited neutralizing antibodies but require phase 2 advancement. Experts estimate 3–10 years to full approval absent Operation Warp Speed-scale acceleration, with disease rarity hindering rapid progress; monitor upcoming phase initiations and funding shifts.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы